Medtronic gains FDA OK for heart resynchronization device

05/7/2013 | Bloomberg Businessweek

The FDA has granted Medtronic approval to market its Viva system, an implantable device used to treat heart failure by resynchronizing the beating of a patient's heart. Patients who received the device saw 21% reduced hospitalizations during the first year of implantation compared with those using traditional systems, a company official said.

View Full Article in:

Bloomberg Businessweek

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC